Estriol, Vaginal Estrogen, and What "Local" Means

Episode Eight | Companion Paper

Written so you can read it slowly, look up the sources, and bring your questions to your own clinician

A woman has had four urinary tract infections in six months. She has gone through menopause. Each time she is given an antibiotic, and each time she is told some version of this is part of getting older.

The infections are real and the antibiotics treat them. What nobody treats is the reason they keep happening. Meanwhile she is told her body will adapt. It does not adapt. Left alone, this tissue does not hold steady. It moves in one direction.

This paper is about that tissue, about the medicine that treats it, and about several things women are rarely told before they are handed a prescription.

Start with the word "local"

Local hormone care means the medicine is placed in the tissue that needs it, and very little of it travels anywhere else.

Two ideas have to stay attached to each other. Local does not mean trivial. This is a medical treatment for a medical condition, not a skin cream and not a comfort product, and it deserves the same care and precision as anything else prescribed. And systemic does not automatically mean dangerous. Hormone therapy that moves through the body is not the reckless choice by default.

Most of the confusion in this area comes from people keeping one half of that sentence and dropping the other.

There is more than one estrogen

The word estrogen gets used as though it names one substance. It names a family.

Estradiol, the main estrogen of the reproductive years. It acts across many systems, not only reproductive ones.

Estrone, the estrogen that becomes more prominent after menopause. It is a weaker signal at the receptor.

Estriol, the gentlest of the three, and the one most associated with pregnancy.

Estriol has one feature that matters for this conversation. It is a one-way street. The body cannot convert it back into the stronger estrogens. For a woman who wants the tissue treated but has real hesitation about estradiol, that property is often the reason estriol is chosen.

Why the way you take a hormone changes what your body receives

When estrogen is swallowed, it passes through the liver before it reaches the rest of the body. The liver converts a large share of it into estrone, the weaker signal. This is ordinary physiology rather than a flaw in anyone's prescription, and it is well described.

So a woman can take an estrogen pill faithfully, every day, and end up with a great deal of the weaker estrogen circulating and less of the stronger one. Routes that do not pass through the liver first behave differently and keep the balance closer to what the body made on its own.

This is not an argument that one route is correct for everyone. It is the reason a single word, estrogen, can describe two very different situations inside two different women.

What the studies actually did, and what they never measured

You will hear, often, that hormone therapy taken for the whole body does not adequately reach this tissue, so a separate local treatment is usually needed. That claim appears in patient handouts, review articles, and guidance documents.

It is worth knowing where it came from. The figures in circulation trace to work from the 1990s and have been repeated ever since rather than re-examined. In those studies every woman received the same fixed dose. Nobody was adjusted upward. Nobody had a level to reach.

And the blood was not checked. The women in that research were not tested to find out how much estrogen the treatment had actually delivered to them.

If a woman takes hormone therapy and her symptoms remain, there are two possible explanations. One is that her tissue cannot respond. The other is that not enough ever arrived. Research that never measures the second one cannot tell you which happened.

There is a further wrinkle. Much of that older research used a form of estrogen quite different from estradiol, and the blood tests available at the time were unreliable at the low levels being measured. So even where something was checked, the number could not carry much weight.

None of this means local therapy is unnecessary. It means the reason usually given for it has not been tested the way people assume it has.

What that changes for you

It does not change anything you should do on your own. It changes the order of the questions.

The common sequence is that symptoms persist, so something gets added on top of what is already being taken. A better sequence asks a question first. What is the current treatment actually delivering? That is answered with bloodwork, and it is not routinely done.

Adding a second treatment on top of an unmeasured first one may still turn out to be right. It should not be mistaken for an answer.

The urinary infections are a real exception

Most of this paper describes an open question. This part is not open, and it is the strongest evidence in the whole subject.

For urinary tract infections that keep returning after menopause, estrogen placed directly in the tissue has genuine trial evidence behind it. The lining of the urethra and bladder opening recovers, the natural acidity returns, the healthy bacteria come back, and the environment stops inviting infection.

Four infections in a year is not bad luck. It is often a tissue problem being repeatedly treated as an infection problem. Antibiotics treat the episode and do nothing about the reason it keeps arriving.

Estrogen is not the only player in this tissue

This is the most overlooked part of the subject.

Estrogen builds the lining, shifts the acidity, supports blood flow, and matters a great deal for the whole urinary and genital tract. It is not working alone. Androgens, the hormone family that includes testosterone, are also part of how this tissue stays healthy, and vaginal tissue has its own local machinery for using them.

Some symptoms that look like an estrogen problem are not one. When treatment is not working, that is information worth examining rather than a reason to keep increasing the same thing. Conditions of the vulvar skin, pain conditions with their own causes, infection, and pelvic floor problems all live in this territory and none of them answer to more estrogen.

Intimacy, transfer, and consent

Here is something rarely said out loud when this prescription is written.

When vaginal estrogen cream is used and intercourse follows soon after, some of the medicine transfers to a partner. This has been measured. Her level goes down and his goes up. The amounts found in partners have been small, and far below the exposure that already carries explicit warnings for other hormone products used on the skin. Small is not the same as nothing, and it is not the same as disclosed.

Two people have a stake in that. A partner has a reasonable claim to know what is happening. And you have a claim to understand it fully, which is the part that usually gets skipped.

Consent is not the signature on a form. Consent is understanding, held by you, deeply enough that you could explain it to someone else.

When is it safe? Nobody has studied it

The obvious next question is how long to wait. If the cream is applied, how much time has to pass before there is nothing left to transfer?

There is no study that answers this. Not one. Research exists showing that transfer happens. No research has measured how much medicine remains on the tissue an hour later, or four hours later, or overnight. Any specific waiting time you are given, by anyone, is an estimate rather than a finding.

This matters for a second reason that has nothing to do with a partner. Many women apply the cream shortly before intimacy, precisely so that intimacy is not painful. That timing means some of the dose is removed rather than absorbed. A woman can conclude the treatment failed her when she was quietly washing it away, and nobody ever mentioned it.

The practical guidance available today is to apply it afterward rather than immediately before, because that leaves the longest stretch before the next occasion. That is an honest answer rather than a clean one. Different forms of local estrogen behave differently, so this is a worthwhile question to ask about the specific one you were given.

This is care you keep, not a course you finish

Local estrogen maintains the tissue. When it stops, the tissue gradually returns to where it was. It works the way watering a garden works, and the plan should include what staying on it looks like.

Knowing that at the start is part of agreeing to it. Learning it two years later, when someone tells you to stop and everything comes back, is not.

Questions worth bringing to your clinician

• What exactly are we treating, and how will we know whether it is working?
• If I am already on hormone therapy, how do we know what it is actually delivering to me?
• Should we be checking my levels, and how often?
• Could my symptoms be something other than a hormone problem?
• What role might androgens play here, and should that be looked at?
• When should I apply this in relation to intimacy?
• What would make us change the plan?

The goal is not to arrive as your own physician. It is to arrive able to participate.

Please read this part

• Do not start, stop, increase, decrease, or change any hormone therapy based on this paper, a podcast episode, an article, or a comment thread. These changes belong in a conversation with a qualified clinician who knows your history.
• Any bleeding after menopause should be evaluated by a clinician, whatever treatment you are using.
• If you have had a hormone-sensitive cancer, these decisions are made together with your oncology team rather than around them.

Understanding your care and directing it by yourself are different things. This paper is for the first one.

Sources

These are provided so you can read them yourself and see where this comes from. Several are technical. You do not need to understand every one of them to use this paper.

On the label change

United States Food and Drug Administration. Announcement removing the boxed warning from menopausal estrogen therapy products, November 10, 2025. The endometrial cancer warning was retained for systemic estrogen-alone products.

On where the "systemic is not enough" claim came from

Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing. Maturitas. 1995;22(Suppl):S31–S33.

On what happens when estrogen is swallowed

Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3–63.

Kuiper GGJM, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138(3):863–870.

On the reliability of older blood tests for estrogen

Santen RJ, et al. Menopause. 2020;27(3):361–370. Reviews the difference between older immunoassay methods and mass spectrometry for measuring estradiol at low concentrations.

On urinary tract infections and local estrogen

Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. New England Journal of Medicine. 1993;329(11):753–756.

Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring on recurrent urinary tract infections in postmenopausal women. American Journal of Obstetrics and Gynecology. 1999;180(5):1072–1079.

On urinary symptoms and estrogen taken by mouth

Cody JD, Jacobs ML, Richardson K, Moehrer B, Hextall A. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database of Systematic Reviews. 2012;10:CD001405.

Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935–948.

Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: the Heart and Estrogen/Progestin Replacement Study. Obstetrics and Gynecology. 2001;97(1):116–120.

On androgens in this tissue

Labrie F. Intracrinology and menopause: the science describing the cell-specific intracellular formation of estrogens and androgens. Menopause. 2019;26(2):220–224.

Cellai I, et al. Insight on the intracrinology of menopause: androgen production within the human vagina. Endocrinology. 2021;162(2):bqaa219.

On transfer to a partner

Hurst BS, Jones AI, Elliot M, Marshburn PB, Matthews ML. Absorption of vaginal estrogen cream during sexual intercourse: a prospective, randomized, controlled trial. Journal of Reproductive Medicine. 2008;53(1):29–32.

Merriam KS, Leake KA, Elliot M, Matthews ML, Usadi RS, Hurst BS. Sexual absorption of vaginal progesterone: a randomized control trial. International Journal of Endocrinology. 2015;2015:685281.

On how long a vaginal medicine remains present

Brown J, Hooper G, Kenyon CJ, et al. Spreading and retention of vaginal formulations in post-menopausal women as assessed by gamma scintigraphy. Pharmaceutical Research. 1997;14(8):1073–1078. This measures how long formulations remain present. No published study measures how much medicine remains available to transfer at a given hour after use.

This paper is education. It is not a treatment protocol, not a recommendation for any particular product or route, and not a substitute for care from a clinician who knows your history.

Protea Institute. The Hormone Literacy Series.